Successful unconventional precision treatment of inflammatory hormone receptor-positive breast cancer guided by molecular profiling.

Document Type

Article

Publication Date

3-7-2025

Publication Title

NPJ precision oncology

Abstract

We present a unique case of locally advanced, inflammatory hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer in a young woman. A MammaPrint gene signature performed on the core biopsy indicated a very high risk of recurrence (MammaPrint high risk 2, MPH2). BluePrint 80-gene signature was used for the molecular subtyping and identified the tumor as a basal subtype, resembling triple-negative breast cancer (TNBC) despite the strong estrogen receptor (ER) expression on immunohistochemical (IHC) staining. We treated the patient with a TNBC protocol, incorporating carboplatin and immunotherapy into the anthracycline-based chemotherapy backbone in the neoadjuvant setting. The patient achieved a complete response and remains to be disease-free after 2 years, with ongoing follow-up.

Volume

9

Issue

1

First Page

63

DOI

10.1038/s41698-025-00845-5

ISSN

2397-768X

PubMed ID

40055517

Link to Full Text

Share

COinS